EXV4:F:F-iShares STOXX Europe 600 Health Care UCITS ETF (DE) (EUR)

ETF | Others |

Last Closing

USD 106.1

Change

0.00 (0.00)%

Market Cap

N/A

Volume

2.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-14 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

-0.02 (-0.06%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.07 (+0.14%)

USD 114.95B
SXR8:F iShares Core S&P 500 UCITS ETF..

-0.30 (-0.05%)

USD 98.13B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+0.08 (+0.14%)

USD 91.82B
XDNY:F Xtrackers MSCI Japan ESG Scree..

N/A

USD 54.47B
VUAA:F Vanguard S&P 500 UCITS Acc

-0.63 (-0.58%)

USD 51.63B
VUSA:F Vanguard Funds Public Limited ..

-0.48 (-0.45%)

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

-0.15 (-0.06%)

USD 50.58B
XJSE:F Xtrackers II - Japan Governmen..

-0.04 (-0.47%)

USD 40.89B
0ZC:F Zscaler Inc

-5.50 (-2.70%)

USD 37.92B

ETFs Containing EXV4:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain 22.38% 51% F 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 22.38% 51% F 58% F
Average Annual (5 Year Horizon)  
Capital Gain 4.69% 53% F 55% F
Dividend Return 4.69% 51% F 49% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.03% 74% C 99% N/A
Risk Adjusted Return 58.37% 65% D 74% C
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike